Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.

Article Details

Citation

Copy to clipboard

Jullien N, Makritis A, Georgiadis D, Beau F, Yiotakis A, Dive V

Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.

J Med Chem. 2010 Jan 14;53(1):208-20. doi: 10.1021/jm9010803.

PubMed ID

19899765 [ View in PubMed

]

Abstract

A new series of phosphinic inhibitors able to interact with both angiotensin-converting enzyme (ACE) C-domain and endothelin-converting enzyme-1 (ECE-1), while sparing neprilysin (NEP), has been developed. The most potent and selective inhibitor in this series (compound 8(F2)) displays K(i) values of 0.65 nM, 150 nM, 14 nM and 6.7 microM toward somatic ACE C-domain, ACE N-domain, ECE-1, and NEP, respectively. Remarkably, in this series, the inhibitor's ability to discriminate between ECE-1 and NEP was observed to depend on the stereochemistry of the residue present in the inhibitor's P(1)' position. After iv administration, compound 8(F2) (10 mg/kg) lowered mean arterial blood pressure by 24 +/- 2 mmHg in spontaneously hypertensive rats, as compared with controls. Mixed ACE/ECE-1 inhibitor may lead to a new generation of vasopeptide inhibitors that should reduce the levels of angiotensin-II and endothelin-1, without interfering with bradykinin cleavage.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Omapatrilat	Angiotensin-converting enzyme	Ki (nM)	6	N/A	N/A	Details
Omapatrilat	Neprilysin	Ki (nM)	9	N/A	N/A	Details
Phosphoramidon	Neprilysin	IC 50 (nM)	30	N/A	N/A	Details